

---

primary studies - published RCT

## Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.

**Code:** PM27852955

**Year:** 2017 **Date:** 2017

**Author:** Muhlebach MS

### Study design (if review, criteria of inclusion for studies)

Non-blinded randomised controlled trial

### Participants

45 clinically stable cystic fibrosis patients (44% female, 4-45 years, mean age 11.5 years) with newly positive methicillin resistant *Staphylococcus aureus* (MRSA) cultures.

### Interventions

a non-blinded eradication protocol (Rx) compared with observation (Obs). The Rx protocol was: oral trimethoprim-sulfamethoxazole or if sulfa-allergic, minocycline plus oral rifampin; chlorhexidine mouthwash for 2 weeks; nasal mupirocin and chlorhexidine body wipes for 5 days and environmental decontamination for 21 days.

### Outcome measures

The primary end point was MRSA culture status at day 28.

### Main results

Between 1 April 2011 to September 2014, 45 participants (44% female, mean age 11.5 years) were randomised (24 Rx, 21 Obs). At day 28, 82% (n=18/22) of participants in the Rx arm compared with 26% (n=5/19) in the Obs arm were MRSA-negative. Adjusted for interim monitoring, this difference was 52% (95% CI 23% to 80%, p

### Authors' conclusions

This MRSA eradication protocol for newly acquired MRSA demonstrated microbiological efficacy with a large treatment effect.

<http://dx.doi.org/10.1136/thoraxjnl-2016-208949>

### See also

Thorax 2017;72(4):318-26.

### Keywords

Anti-Bacterial Agents; Bacterial Infections; Infection; Minocycline; Mupirocin; pharmacological\_intervention; Respiratory Tract Diseases; Respiratory Tract Infections; Rifampin; *Staphylococcus aureus*; Cotrimoxazole; Oral; Sulfonamides; other anti-bacterial agents; Tetracyclines;